• Pandia Health is a doctor founded and led telehealth company, offering online prescriptions and free delivery designed to make it easier for women to access birth control options that meet their needs
  
• Partnership represents first telehealth alliance for Agile’s Twirla^® birth control patch

PRINCETON, N.J., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced a partnership with Pandia Health, an online telehealth service, which will establish the first telehealth relationship for Agile and offer an additional point of access to Twirla^® (levonorgestrel and ethinyl estradiol) transdermal system in a fast-growing channel.

Pandia Health offers convenient prescription fulfillment for women with active birth control prescriptions, as well as access to expert birth control doctors who can provide prescriptions through asynchronous online visits. All patients receive free delivery of their birth control. The Company and Pandia plan to phase in the availability of Twirla in the second half of 2021.

“The telehealth channel is growing in importance, and our goal was to find a partner that shares our values and focus on women’s health. We are thrilled to partner with Pandia Health, a truly innovative leader in this space, and we think this relationship allows Agile to offer another point of access to Twirla^® as more women choose telehealth for their contraceptive needs,” said Amy Welsh, Vice President of Marketing at Agile Therapeutics. “The team at Pandia shares our commitment to listening -- and responding -- to what women need with regard to their birth control options.”

“Pandia Health’s mission is to make women’s lives easier by bringing birth control to women wherever they have internet and a mailbox,” said Dr. Sophia Yen, founder of Pandia Health. “As the only doctor-led, women-founded, women-led birth control delivery company, we are excited to partner with a women’s healthcare company like Agile Therapeutics to pursue affordable access to another method of birth control.”

The use of telehealth in contraceptive care has grown over the past several years and has come into the spotlight during the COVID-19 pandemic. A recent article in the reproductive health journal Contraception examined trends in how women accessed contraceptive care during the COVID-19 pandemic, finding a decrease for in-person visits and a subsequent increase in the use of telehealth. A 2020 report by the Guttmacher Institute found that 24 percent of women using the pill reported that, because of the pandemic, they had switched to a telemedicine appointment with their health care provider to have their prescription refilled.

About Agile Therapeutics, Inc.
Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol) transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website.

About Pandia Health
Pandia Health is the only doctor-led, women-founded, women-led telehealth company. Pandia Health offers patients asynchronous online visits with expert birth control doctors and free delivery. Sophia Yen, M.D., M.P.H., co-founded Pandia Health in 2016 and is passionate about making women’s lives easier, preventing unplanned pregnancies, and educating women about reproductive health. Pandia Health makes women’s lives easier by providing a one-stop shop for recurring medications, starting with birth control. From affordable telehealth to prescription fulfillment and medicine delivery, Pandia Health is reinventing the way patients get their prescription medication.

Forward-Looking Statement

Certain information contained in this press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We may in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements regarding our ongoing and planned manufacturing and commercialization of Twirla®, the potential market acceptance and uptake of Twirla, including the increasing demand for Twirla, our results of operations, growth and strategies, the expected benefits of our marketing and sales distribution strategies. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to our ability to maintain regulatory approval of Twirla, the ability of Corium to produce commercial supply in quantities and quality sufficient to satisfy market demand for Twirla, our ability to successfully commercialize Twirla, the accuracy of our estimates of the potential market and the market demand for Twirla, regulatory and legislative developments in the United States and foreign countries, our ability to obtain and maintain intellectual property protection for Twirla, our strategy, business plans and focus, the effects of the COVID-19 pandemic on our operations and the operations of third parties we rely upon as well as on our potential customer base and the other risks set forth in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contact: 

Matt Riley
Head of Investor Relations & Corporate Communications
mriley@agiletherapeutics.com